Superpower Tirzepatide Review: Tirzepatide Access & Unresolved Total Cost

Superpower has a public tirzepatide intake pathway and a broader laboratory-focused membership. The offer is worth distinguishing from a simple medication subscription: the public material does not establish a dependable total for tirzepatide plus any required membership.¹

Superpower is easier to evaluate if the broader testing membership has independent value to you. A tirzepatide-specific quote is still needed; the semaglutide figure cannot answer that question.

What the advertised price buys

The tirzepatide quiz contains a $249 monthly amount in a section, but the nearby text explicitly assigns that number to compounded semaglutide. That amount should not be used to estimate a tirzepatide prescription. Obtain a written tirzepatide-specific price rather than carrying that number into a comparison.¹

How the care arrangement works

The broader program emphasizes testing and access to a care team. Its current membership starts at $349 per year, with pricing qualifications for New York and New Jersey. Ask whether membership is required for the prescription pathway, what the initial bill includes and which laboratory services or clinical visits remain additional.⁴

Pharmacy, eligibility and payment terms

The quiz explicitly says tirzepatide is unavailable in some states and describes patient-specific compounded prescribing. Actual clinician eligibility, pharmacy assignment and prescription cancellation terms remain to be confirmed.¹

Do you want the broader membership independently?

Superpower is easier to evaluate if you first decide whether the laboratory-focused membership is something you want even without a tirzepatide prescription. If the answer is yes, ask what medication care adds to that purchase. If the answer is no, ask whether a standalone prescription pathway is available and what it costs. The public price language shows why drug identity matters as much as the number. Require the final quote to name tirzepatide, identify all required membership charges and confirm state eligibility before treating it as an available offer.

Compare Allara Health when broader medical and nutrition care is the priority and Lemonaid Health for a distinct care membership with separate medication charges. Superpower’s testing membership needs its own value assessment before comparing a prescription add-on.

Superpower’s separate membership and medication questions can be compared with Zepbound costs, our compounded medication guide and the distinction between tirzepatide and semaglutide. The quiz’s semaglutide price is not a tirzepatide quote.

Compounded products are not FDA-approved. FDA advises using them only when an individual patient’s medical needs cannot be met by an approved drug.³

Membership and medication need separate estimates

A membership starting at $349 annually is a larger initial purchase than a small monthly figure suggests, even if dividing it by twelve produces an equivalent below $30. That calculation does not establish monthly billing. Ask whether the full annual fee is required at enrollment, whether it is required for tirzepatide access and whether medication care has another professional fee. Confirm any state-specific price difference and extra cost for at-home laboratory collection.⁴

Someone already seeking broad laboratory testing may reasonably value the membership before considering medication. Someone seeking only a prescription should not assume the same value. The relevant comparison is what the person intends to use, rather than the number of tests advertised in a general membership package.

What the tirzepatide pathway establishes

The public material describes patient-specific compounded prescribing and says the medication is unavailable in some states. It also emphasizes clinician review of health history. These details support describing an offer, but do not establish a prescription, state eligibility or final checkout total for an individual reader.¹

Ask which medical group handles treatment, which pharmacy will dispense and how follow-up differs from general membership support. If laboratory monitoring is proposed, ask which testing is required for the medication and what happens to the membership if the clinician decides against prescribing. A proposed testing-and-care bundle can have value, but that value should be assessed after the separate clinical and financial obligations are made clear. Until then, the missing tirzepatide-specific quote is a material limit rather than a number that can safely be inferred from semaglutide advertising.